Similar to TCGA, the OS and PFS of patients with CDX2-suppressed colon cancers in the Sidra-LUMC AC-ICAM cohort were not different from the OS and PFS of patients with non-CDX2-suppressed colon cancers (Log Rank test p = 0.53 and 0.4, respectively), although the numbers in the cohorts and events were lower. This evidence concerns the gene CDX2 and malignant colon neoplasm.